NUCYNTA®, a molecule with mu-opioid agonist activity and norepinephrine reuptake inhibition, has been approved for the relief of moderate to severe acute pain in patients 18 years of age or older. NUCYNTA® has been clinically tested in multiple pain models and found to combine opioid efficacy with favorable gastrointestinal tolerability. Click here for pdf.